| Followers | 905 |
| Posts | 39660 |
| Boards Moderated | 7 |
| Alias Born | 03/22/2016 |
Monday, August 19, 2024 7:11:41 AM
54 MILLION SHORT IN THE LAST TWO SESSIONS..THEY HAVE BEEN BUILDING THEIR POSITIONS, FREAKS THAT SAY SHORTS IN TROUBLE ARE CLUELESS...THEY ARE READY TO PULL THE RUG TO FILL THE GAP
Recent CING News
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25 • Newsfile • 04/06/2026 08:34:00 PM
- Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights • GlobeNewswire Inc. • 03/18/2026 12:00:00 PM
- Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 02/17/2026 01:00:00 PM
- Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25 • Newsfile • 11/18/2025 09:27:00 PM
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 01:00:00 PM
- Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 • GlobeNewswire Inc. • 11/10/2025 01:00:00 PM
- Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting • GlobeNewswire Inc. • 10/23/2025 08:45:00 PM
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date • GlobeNewswire Inc. • 10/14/2025 12:00:00 PM
- Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment • GlobeNewswire Inc. • 09/17/2025 12:45:00 PM
- Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights • GlobeNewswire Inc. • 08/19/2025 12:45:00 PM
- Cingulate Provides Management Team Update • GlobeNewswire Inc. • 08/15/2025 01:00:00 PM
- Cingulate Submits New Drug Application to FDA for Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 08/06/2025 12:45:00 PM
- Cingulate Receives $4.3M Waiver from FDA Ahead of Imminent Filing for Marketing Approval of Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 07/29/2025 12:00:00 PM
- Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application • GlobeNewswire Inc. • 07/09/2025 12:00:00 PM
- Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD • GlobeNewswire Inc. • 05/20/2025 12:00:00 PM
- FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301 • GlobeNewswire Inc. • 05/14/2025 12:00:00 PM
- Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets • GlobeNewswire Inc. • 05/08/2025 08:30:00 PM
- Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD • GlobeNewswire Inc. • 04/29/2025 12:00:00 PM
